AstraZeneca
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.About AZN
AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology.
AZN Key Statistics
Stock Snapshot
With a market cap of 301.1B, AstraZeneca(AZN) trades at $194.01. The stock has a price-to-earnings ratio of 29.94 and currently yields dividends of 1.6%.
On 2026-03-06, AstraZeneca(AZN) stock moved within a range of $192.76 to $196.42. With shares now at $194.01, the stock is trading +0.6% above its intraday low and -1.2% below the session's peak.
Trading volume for AstraZeneca(AZN) stock has reached 699.04K, versus its average volume of 2.08M.
The stock's 52-week range extends from a low of $122.48 to a high of $212.71.
The stock's 52-week range extends from a low of $122.48 to a high of $212.71.
AZN News
AstraZeneca ( (GB:AZN) ) has shared an update. AstraZeneca disclosed that Chief Executive Officer Pascal Soriot received an allocation of 101,495 ordinary shar...
Thursday, March 5, 2026 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports...
AstraZeneca ($~AZN) announced an update on their ongoing clinical study. AstraZeneca is updating investors on a phase I trial testing a new drug mix in tough-t...
Analyst ratings
81%
of 31 ratingsMore AZN News
AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. AstraZeneca (GB:AZN) has launched a Phase I trial titled “A Phase I Randomized Si...
AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. The study “Open-label Single-arm, Non-interventional, Multi-centre Study for Eval...
AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. AstraZeneca has started a new early-stage trial to see how its zibotentan/dapagli...
AstraZeneca ($~AZN) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium Unlock hedge fund-level data and powerful investing tool...
Morgan Stanley raised the firm’s price target on AstraZeneca (AZN) to $219 from $109 and keeps an Overweight rating on the shares. The firm said its risk/reward...
An update from AstraZeneca ( (GB:AZN) ) is now available. AstraZeneca has confirmed that as of 28 February 2026 its issued share capital with voting rights sta...
Compugen ( (CGEN) ) has issued an update. Compugen on March 2, 2026, reported fourth-quarter and full-year 2025 results that showcased a dramatically strengthe...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.